Publication | Open Access

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

Sorafenib Versus PlaceboHematological MalignancyOncologyMixed-phenotype Acute LeukemiaHematologyClinical TrialsMyeloid NeoplasiaAcute Myeloid LeukaemiaPharmacotherapyPhase 2MedicineHealth Sciences